

Sildenafil - pulmonary hypertension - India (Repurposing Scan)

Report ID: REP-20251217-8c6e09
Generated At: 2025-12-17T11:23:48.901621
Format: pdf

Executive Summary

- Current guidelines for pulmonary hypertension provide general authoritative recommendations but no specific detailed mention of sildenafil. A PubMed search from 2020 to 2025 yielded no new publications specifically concerning sildenafil and pulmonary hypertension in this period. Recent news includes several regional analyses and comparison studies involving sildenafil for pulmonary hypertension in India and other populations, indicating ongoing clinical interest and application. The presence of news about regulatory approvals also suggests continued importance of sildenafil formulations.

Clinical Trials

Summary

- Active trials: 4
- Completed trials: 1
- Phase distribution: Phase Observational (0) Phase Phase 1 (0) Phase Phase 2 (0) Phase Phase 3 (2) Phase Phase 4 (1)

Highlights

- No Phase III trials identified in India

Top Trials

Trial ID	Title	Phase	Status	Locations	Start Date
NCT04715113	Hemodynamic Effects of Acute Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension: Single-center Randomized Controlled Trial	NA	Completed	Switzerland	2021-02-01
NCT03460470		Phase 3	Active		2018-02-14

Trial ID	Title	Phase	Status	Locations	Start Date
	Sildenafil in US Heart Failure Patients (SilHF-US)			United States	
NCT01616381	Sildenafil in Heart Failure (SilHF); An Investigator Initiated Multinational Randomized Controlled Clinical Trial.	Phase 3	Active	Israel, Italy, Norway, United Kingdom	2013-03
NCT01582438	A Local, Multicentre, Open Label Access Study, To Provide Sildenafil Therapy For Subjects Who Completed A1481156 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil For Subjects In India	Unknown	Active	India	Not available
NCT03053739	Randomized Controlled Trial to Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis	Phase 4	Active	India	2016-12

Guidelines and Literature

Guidelines

- **WHO Guidelines:** Generic authoritative health guideline source (disease-specific guideline not mapped in MVP).
- **NICE Guidelines:** Generic authoritative guideline repository (disease-specific guidance not mapped in MVP).

Publications

Repurposing Options

- **Targeted subgroup usage**

Rationale: Current guidelines for pulmonary hypertension provide general authoritative recommendations but no specific detailed mention of sildenafil. A PubMed search from 2020 to 2025 yielded no new publications specifically concerning sildenafil and pulmonary hypertension in this period. Recent news includes several regional analyses and comparison studies involving sildenafil for pulmonary hypertension in India and other populations, indicating ongoing clinical interest and application. The presence of news about regulatory approvals also suggests continued importance of sildenafil formulations.

Evidence: WHO Guidelines, NICE Guidelines

Risks and Gaps

- Limited late-stage clinical evidence
- Geography-specific data gaps for India

References

- **Guideline:** WHO Guidelines — <https://www.who.int/publications/guidelines>
- **Guideline:** NICE Guidelines — <https://www.nice.org.uk/guidance>
- **Trial:** NCT04715113 — <https://clinicaltrials.gov/study/NCT04715113>
- **Trial:** NCT03460470 — <https://clinicaltrials.gov/study/NCT03460470>
- **Trial:** NCT01616381 — <https://clinicaltrials.gov/study/NCT01616381>
- **Trial:** NCT01582438 — <https://clinicaltrials.gov/study/NCT01582438>
- **Trial:** NCT03053739 — <https://clinicaltrials.gov/study/NCT03053739>

Warnings

- **FTO requested but not executed in MVP**
- **Supply view requested but not executed in MVP**